Latest Breaking News On - Johan hartman - Page 3 : comparemela.com

First CE-IVD marked AI solution for prognostic risk stratification of breast cancer patients. | Comunicados | Edición USA

Veracyte, Inc.: Veracyte Announces Further European Reimbursement Expansion for Prosigna Breast Cancer Test

Only Test of Its Kind to Be Recommended for Use in All Swedish Healthcare Regions Without Restrictions Veracyte, Inc. (Nasdaq: VCYT) today announced that the Swedish Medical Technologies Product

Veracyte Announces Further European Reimbursement Expansion for Prosigna Breast Cancer Test

Press release content from Business Wire. The AP news staff was not involved in its creation.

AI-based tool set to improve breast cancer diagnosis

An AI-based tool that improves breast cancer diagnosis and predicts the risk of recurrence has been developed by researchers in Sweden.

New AI-based tool improves the diagnosis of breast cancer tumors

Researchers at Karolinska Institutet in Sweden have developed an AI-based tool that improves the diagnosis of breast cancer tumors and the ability to predict the risk of recurrence.